Do you want to read an article? Please log in or register.
Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
Type 2 Diabetes
Related content
Diabetes - GeneralType 2 DiabetesObesity and Bariatric Surgery
Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
Diabetologia.
Eriksson JW, Lundkvist P, Jansson PA, Johansson L, Kvarnström M, Moris L, Miliotis T, Forsberg GB, Risérus U, Lind L, Oscarsson J
doi: 10.1007/s00125-018-4675-2.
Type 2 Diabetes
The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients
Diabetes Care.
Latva-Rasku A, Honka MJ, Kullberg J, Mononen N, Lehtimäki T, Saltevo J, Kirjavainen AK, Saunavaara V, Iozzo P, Johansson L, Oscarsson J, Hannukainen JC, Nuutila P
doi: 10.2337/dc18-1569.
COMMENTED
Type 2 Diabetes
Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial
★ 3
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Diabetes Care
Dubourg J, Fouqueray P, Thang C, Grouin JM, Ueki K
doi: 10.2337/dc20-0763
Diabetes - GeneralType 2 Diabetes
Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial
Lancet Diabetes Endocrinol.
Parvanova A, Trillini M, Podestà MA, Iliev IP, Ruggiero B, Abbate M, Perna A, Peraro F, Diadei O, Rubis N, Gaspari F, Carrara F, Stucchi N, Belviso A, Bossi AC, Trevisan R, Remuzzi G, de Borst M, Ruggenenti P; PROCEED Study Organization and the Scientific Writing Academy (SWA) 2016
doi: 10.1016/
Further Publications
Henagliflozin Monotherapy in Patients with Type 2 Diabetes Inadequately Controlled on Diet and Exercise: A Randomized, Double-blind, Placebo-controlled, Phase 3 Trial
Diabetes Obes Metab
Lu J, Fu L, Li Y, Geng J, Qin L, Ping L, Zheng H, Sun Z, Li Y, Zhang L, Sun Y, Chen D, Qin G, Weiping L, Guo Y, Zhang Y, Liu H, Zhang T, Zou J
doi: 10.1111/dom.14314
RECOMMENDED
Type 2 Diabetes
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
Lancet.
Pratley R, Amod A, Hoff ST, Kadowaki T, Lingvay I, Nauck M, Pedersen KB, Saugstrup T, Meier JJ, PIONEER 4 investigators
doi: 10.1016/S0140-
COMMENTED
Type 2 Diabetes
Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial
Lancet Diabetes Endocrinol.
Pollock C, Stefánsson B, Reyner D, Rossing P, Sjöström CD, Wheeler DC, Langkilde AM, Heerspink HJL
doi: 10.1016/S2213-8587(19)30086-5.
Diabetes - GeneralType 2 DiabetesGlycemic Control
Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial
JAMA.
Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J
doi: 10.1001/jama.2017.14752.
Glycemic Control
Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials
Cardiovasc Diabetol
Yokote K, Yamashita S, Arai H, Araki E, Matsushita M, Nojima T, Suganami H, Ishibashi S
doi: 10.1186/s12933-021-01291-w